Evaluate the Implementation of Using Indocyanine Green for Sentinel Lymph Node Mapping in Breast Cancer Patients

This study is evaluating the use of a fluorescent dye called indocyanine green (ICG) to help surgeons more accurately identify and remove sentinel lymph nodes (the first lymph nodes that cancer might spread to) during breast cancer surgery. Better detection of these nodes can help guide treatment decisions. **You may be eligible if...** - You have been diagnosed with breast cancer (DCIS or invasive cancer, stage T1–T3) by biopsy - Imaging confirms no cancer spread to the armpit lymph nodes - You are scheduled for breast cancer surgery that includes sentinel lymph node biopsy through an armpit incision - You are 18 or older - You have provided written consent **You may NOT be eligible if...** - You are under 18 years old - Your sentinel lymph node biopsy will be performed through a mastectomy incision - You have a known allergy to ICG, intravenous contrast, or iodine - You have previously had armpit lymph nodes removed - You are pregnant or breastfeeding - There are personal, social, or geographic factors that would prevent you from following the study protocol Talk to your doctor to see if this trial is right for you.